Access
To read this story in full you will need to login or make a payment (see right).
News
Nature Medicine 14, 471 (2008)
doi:10.1038/nm0508-471c
Harsh spotlight falls on Vytorin
Meredith Wadman1
- Washington, DC
It was hard to miss the headlines out of the recent American College of Cardiology meeting in Chicago: Vytorin, the blockbuster cholesterol drug combination from Merck and Schering-Plough, had failed to perform any better than a much cheaper generic medication (simvastatin alone) at fighting plaque buildup in arteries in a randomized, double-blind clinical trial.Less widely reported was the release of angry emails sent by the study's principal investigator, John Kastelein, to a Schering-Plough executive last summer.
To read this story in full you will need to login or make a payment (see right).
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
